CAMBRIDGE, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human
CAMBRIDGE, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human
The multi-target collaboration combines Parabilis’s novel Helicon™ peptide platform with Regeneron’s industry-leading antibody capabilities Agreement provides for Parabilis to receive $125M from Regeneron, including a $50M upfront payment and a $75M equity commitment, with up to approximately $2.2B
CAMBRIDGE, Mass.--( BUSINESS WIRE)-- Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines using its Helicon™ peptide platform to drug historically undruggable targets, today announced the appointment of Alan M.
Helen Ho, Ph.D. joins Parabilis as Chief Business and Strategy Officer to advance corporate growth strategy and scale business development impact Thomas Kotarakos promoted to Chief Financial Officer to shape financial strategy in support of continued execution across the company’s clinical and
Latest milestone underscores accelerating regulatory momentum for the company’s lead investigational Helicon peptide, following FDA Fast Track Designation in desmoid tumors CAMBRIDGE, Mass.--( BUSINESS WIRE)-- Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating
Preliminary clinical data presented at the InSiGHT Biennial Meeting demonstrate significant reductions in duodenal polyposis and the size of the co-existing desmoid tumor in a patient from the ongoing Phase 1/2 trial of zolucatetide CAMBRIDGE, Mass.--( BUSINESS WIRE)-- Parabilis Medicines, a
Financing co-led by RA Capital Management, Fidelity Management & Research Company, and Janus Henderson Investors CAMBRIDGE, Mass.--( BUSINESS WIRE)-- Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer using its
Consistent, significant tumor reductions across all ACP patients mark the second low-complexity Wnt/β-catenin-driven tumor subgroup – alongside desmoid tumors – showing uniform monotherapy activity in multiple patients treated with FOG-001 CAMBRIDGE, Mass.--( BUSINESS WIRE)-- Parabilis Medicines, a
Milestone follows disclosure of compelling preliminary data presented at the ESMO Congress and the CTOS 2025 Annual Meeting showing clinically meaningful anti-tumor activity in desmoid tumors CAMBRIDGE, Mass.--( BUSINESS WIRE)-- Parabilis Medicines, a clinical-stage biopharmaceutical company
